An echocardiographic nomogram incorporating factors such as asymmetric hypertrophy (OR 3.729) and granular sparkling demonstrated high accuracy in identifying cardiac amyloidosis in patients with left ventricular hypertrophy.
Cohort (n=1,398)
Sí
Does an echocardiographic nomogram accurately identify cardiac amyloidosis in patients with left ventricular hypertrophy?
A novel echocardiographic nomogram incorporating routine parameters and the AMYLI score demonstrated high accuracy for screening cardiac amyloidosis in patients with left ventricular hypertrophy.
Estimación del efecto: OR 3.729 (95% CI 1.884-7.441)
Tasa de eventos absoluta: 27.2% vs 10.2%
valor p: p=<0.001
BACKGROUND: Echocardiography is the principal non-invasive imaging modality for screening cardiac amyloidosis (CA). This study aimed to establish a cohort of CA-associated left ventricular hypertrophy (CA-LVH) within a hospital-based population and to develop an echocardiographic identification model for CA using readily available echocardiographic parameters. METHODS: This retrospective nested cohort study involved the collection of clinical and echocardiographic data from three hospitals affiliated with the West China Medical Center, Sichuan University, between January 1, 2008, and December 31, 2023. The relative wall thickness (RWT) was calculated as twice the left ventricular posterior wall thickness (LVPW) divided by the left ventricular internal diameter (LVID). Asymmetric hypertrophy was defined as a ratio of interventricular septal thickness (IVS) to LVPW greater than 1.3. The AMYLI score was computed as the product of RWT and E/e' ratio. RESULTS: A total of 185 CA patients (183 AL-CA and 2 ATTR-CA) who underwent 309 echocardiography examinations from different time periods with 1,213 echocardiographic data points from in-hospital non-CA-LVH cases matched for age, gender, and body surface area were included. Multivariable logistic regression analysis identified a history of hypertension odds ratio (OR): 0.04, 95% confidence interval (CI): 0.021-0.073, LVID OR: 0.927, 95%CI: 0.878-0.977, left ventricular ejection fraction (LVEF) OR: 0.95, 95%CI: 0.908-0.993, AMYLI score OR: 1.088, 95%CI: 1.024-1.161, asymmetric hypertrophy OR: 3.729, 95%CI: 1.884-7.441, granular sparkling OR: 3.111, 95%CI: 1.355-7.431, small pericardial effusion OR: 2.77, 95%CI: 1.563-4.937, mild aortic regurgitation OR: 2.353, 95%CI: 1.278-4.361, mild mitral regurgitation OR: 4.331, 95%CI: 2.347-8.141, and mild tricuspid regurgitation OR: 3.837, 95%CI: 2.026-7.358 as independent predictive factors for CA in LVH patients. The predictive factors were used to construct a nomogram model, which demonstrated high accuracy (0.91-0.92), specificity (0.91-0.92), sensitivity (0.90-0.91), positive predictive value (0.73), negative predictive value (0.93-0.98), and Youden index (0.81-0.83). CONCLUSION: The developed nomogram displayed remarkable predictive accuracy, which has the potential to enhance CA screening via routine echocardiography and strategically guide subsequent diagnostic evaluations.
Liang et al. (Mon,) conducted a cohort in Cardiac amyloidosis in patients with left ventricular hypertrophy (n=1,398). Echocardiographic nomogram (including asymmetric hypertrophy) vs. Non-cardiac amyloidosis left ventricular hypertrophy was evaluated on Asymmetric hypertrophy as an independent predictor of cardiac amyloidosis (OR 3.729, 95% CI 1.884-7.441, p=<0.001). An echocardiographic nomogram incorporating factors such as asymmetric hypertrophy (OR 3.729) and granular sparkling demonstrated high accuracy in identifying cardiac amyloidosis in patients with left ventricular hypertrophy.